INTRODUCTION
============

Recently much attention has been directed toward the study of gene sets in the context of microarray data analysis (hereafter GSA). A microarray experiment typically provides a list of differentially expressed genes (DEGs) ([@gks866-B1],[@gks866-B2]) that represent the starting point of a highly challenging process of result interpretation. The grouping of genes into functionally related entities is of great help for interpreting the results. In this context, statistical methods for the identification of groups of functionally related genes with moderate, but coordinated, expression changes are fundamental to help biologists in the process of results comprehension.

Several GSA tests, both univariate and multivariate, have been recently developed ([@gks866-B3; @gks866-B4; @gks866-B5; @gks866-B6; @gks866-B7]). GSA methods can be divided into two broad categories: (i) methods based on enrichment analysis performed on a list of genes selected through a gene-level test; and (ii) methods based on global and multivariate approaches that define a model on the whole gene set ([@gks866-B8]). In general these two approaches are based on two fundamentally different null hypotheses: the first type hypothesizes the same level of association of a gene set with the given phenotype as the complement of the gene set (say, Q1). The second type only considers the genes within a gene set and hypothesizes that there is no gene in the gene set associated with the phenotype (say, Q2) ([@gks866-B9]). Goeman and Buhlmann ([@gks866-B5]) termed these approaches *competitive* and *self-contained*, respectively. The main drawbacks with *competitive* methods are (i) the assumption that genes are independent; and (ii) the use of a cut-off threshold for the selection of DEGs. In this way, many genes with moderate but meaningful expression changes are discarded by the strict cut-off value, which leads to a reduction in statistical power. On the other hand, global and multivariate approaches relax the assumption of independence among genes belonging to the same gene sets and identify moderate, but coordinated, expression changes that cannot be detected by the previous approach without depending from any arbitrary cut-offs.

In general, the *a priori* definition of gene sets is obtained from Gene Ontology (GO) ([@gks866-B10]) information or from biological pathways; while genes belonging to a GO category do not have any explicit connections among them (apart from being involved in the same function), genes in the same pathway are structured in a network with explicit biological interactions. Almost all of the *self-contained* approaches, when applied to biological pathways, use merely the list of genes belonging to a pathway, and therefore, although effective, miss the relevant topological information contained.

In the last years, little effort has been done to consider the topological information within the *self-contained* GSA methods. The seminal paper by Draghici *et al.* ([@gks866-B4]) proposed an interesting approach (called Impact Analysis, `SPIA (`[@gks866-B11])) attempting to capture several aspects of the data: the fold change of DEGs, the pathway enrichment and the topology of signaling pathways. In particular, `SPIA` enhances the impact of a pathway if the DEGs tend to lie near its entry points. Recently, Isci *et al.* ([@gks866-B6]) proposed a Bayesian pathway analysis that models each biological pathway as a Bayesian network and considers the degree to which the model fits the observed experimental data. Both approaches test the whole pathway without providing the user with the portions of the pathway that are effectively associated with the phenotype. This is an essential information especially when the pathway is large.

To this end, Laurent *et al.* ([@gks866-B12]) developed a graph-structured two-sample test of means for problems in which the distribution shift is assumed to be smooth on a given graph and devised branch and bound algorithms to systematically apply their test to the subgraphs of a large graph, without enumerating and testing these subgraphs one-by-one. Alternatively, Massa *et al.* ([@gks866-B13]) introduced an innovative approach based on Gaussian graphical models that tests both differences in mean and in covariance matrices between two experimental conditions. In particular, the graphical models context is useful to decompose the overall graph (obtained from the pathway) into smaller parts (cliques), that can be explored and tested in detail.

An alternative approach was proposed by Emmert-Streib ([@gks866-B7]) that proposes to infer the undirected dependency graphs representing pathways. Briefly, given two groups, Emmert-Streib ([@gks866-B7]) infers the dependency structure of genes belonging to the same GO group using Pearson correlation and partial Pearson correlation independently on both groups, and then tests the similarity of the inferred graphs using a graph edit distance and a permutational approach.

In this work, we take the starting point that pathways are the best representation of biological experimentally validated knowledge of a specific process. In fact, the annotation of a biological pathway is the result of an extensive effort of hundreds of researchers that manually codify their experimental knowledge about a specific biological process into a graphical representation. Therefore, we decide to consider the topology of the pathway as fixed.

Following Massa *et al.* ([@gks866-B13]), we propose an empirical two-step method, called `clipper` hereafter, for the identification of significant signal transduction paths within significantly altered pathways. In particular: (i) we generalize the approach of Massa *et al.* ([@gks866-B13]) to the case of *P* ≫ *n* (with *P* number of genes/variables and *n* number of samples/replicates), using shrinkage and a graphical lasso penalty estimators of the covariance matrices; and (ii) by exploiting the structure of a junction tree derived from an initial graph, we propose a procedure to highlight the portions, called signal paths, of a pathway mostly correlated with the phenotype.

We test our approach on simulated and real expression datasets of completely different biological problems (cancer and muscle disorders). The obtained results provide evidence of the success of our approach in the detection of altered pathways and, more importantly, in the identification of novel signal paths. We believe that `clipper` could become an important tool for gene expression data interpretation.

MATERIALS AND METHODS
=====================

To implement topology-based GSA using microarray data, we need first to convert pathways into gene networks, i.e. into a graphical structure in which a node represents a simple element like a gene/protein ([@gks866-B14]). In fact, whereas pathway nodes might consist of multiple entities such as protein complexes, gene family members and chemical compounds, microarrays measure each single element of complexes and gene family separately. Here, we used `graphite (`[@gks866-B14]), a Bioconductor package addressing these issues. In general, `graphite` takes pathway information from four different databases (Biocarta; KEGG, ([@gks866-B15]); NCI/Nature Pathway Interaction Database, ([@gks866-B16]); Reactome, ([@gks866-B17])) and this information is interpreted and opportunely coded by following specific biologically driven rules. Specifically, given a pathway structure, `graphite` converts it into a gene--gene network. We refer to the manual of the package for more information on the conversion.

Pathways may be cyclic or acyclic. The number of pathways with cycles is dependent either on the structure of the graph or on the number of genes in the array, but fortunately is quite small. Given that the graphical inference methods assume to have an acyclic graph we preventively eliminate self-loops and solve cycles removing the weakest edge of the cycle based on expression data (with minimum expression profile correlation between nodes) (see also ([@gks866-B18])).

Then, an acyclic gene network can be read as a Directed Acyclic Graph (DAG). Most inference methods for a DAG convert the network to an undirected cycle-free graph. Such conversion might require some or all of the following steps: moralization, triangulation, clique identification and junction tree construction. Briefly, moralization inserts an undirected edge between two nodes that have a child in common and then eliminates directions on the edges; triangulation inserts edges in the moralized graph so that in the moralized graph all cycles of size ≥4 have chords, where a chord is defined as an edge connecting two non-adjacent nodes of a cycle; clique identification identifies the cliques of the triangulated graph, i.e. the complete subgraphs having all their vertices joined by an edge; junction tree construction builds a new hyper-tree having cliques as nodes and satisfying the *running intersection property* according to which, for any cliques and in the tree, every clique on the path connecting and contains . As an example, consider the pathway Chronic myeloid leukemia (CML) from KEGG database, see [Supplementary Figure S1](http://nar.oxfordjournals.org/cgi/content/full/gks866/DC1).

STEP 1: TESTING THE WHOLE PATHWAY
=================================

In specific conditions, the strength of molecular interactions within a pathway could be altered, making the pathway a dynamic entity. It is therefore reasonable to test its dynamic perturbation by statistically testing equality of concentration matrices and mean vectors. Here, we assume to have two classes of samples (say cases and controls) and we suggest to model the data in the two experimental conditions with two graphical Gaussian models with the same undirected graph *G*: where *P* is the number of genes (vertices of the graph), and are the concentration matrices (inverse of the covariance matrices) of the two models and is the set of symmetric positive definite matrices with null elements corresponding to the missing edges of *G*. Here, *G* is the graph obtained after transforming the network obtained from `graphite` first into a DAG, and, then, into its moral graph.

In Massa *et al.* ([@gks866-B13]), two tests were proposed, one for the comparison of the strength of the links between genes in the two experimental conditions and another one to test the differential expression of the pathway. In the first case, the hypothesis to be tested is Testing the differential expression of the pathway is achieved by checking equality of means, i.e. Such test has a different structure according to whether the two graphical Gaussian models and are homoschedastic, i.e. they have the same covariance matrix, or not.

Once the graph *G* is known, the null elements in the concentration matrices are identified. On the contrary, are not known and need to be estimated from the data. Here, and are estimated with the corresponding sample means. The maximum-likelihood estimates of and can be obtained by using the Iterative Proportional Scaling algorithm (IPS, see ([@gks866-B19], p.134)) and by taking the sample covariance matrices as starting values. The IPS guarantees that the estimated matrices belong to . In this case, a necessary condition for the existence of the maximum-likelihood estimate is that the number of samples is greater than the cardinality, i.e. the number of nodes of the largest clique ([@gks866-B19], p. 133), a setting that is easily missed in case of gene expression data (a typical microarray experiment does not exceed the few tens of samples per class, and with the advent of deep-sequencing technology, this dimension is further reduced to few units). In [Supplementary Figure S2](http://nar.oxfordjournals.org/cgi/content/full/gks866/DC1), we report the distribution of the cardinality of the largest clique *per* pathway in four different databases. It is worth noting that there are several pathways with clique cardinality of several tens of nodes that would not be processed by the standard IPS algorithm.

To estimate the covariance matrix in such circumstances, `clipper` applies a shrinking procedure in the estimation of the sample covariance matrices. Apart from increased efficiency, the shrunken estimates have the additional advantage of being always positive definite and well conditioned. Here, we use a James--Stein-type shrinkage estimator, as implemented in `corpcor R package` ([@gks866-B20],[@gks866-B21]).

The shrunken estimates are passed on to the IPS algorithm. The use of a shrinkage estimator, however, precludes the use of the asymptotic distribution of the -likelihood ratio test which, in standard settings, has a distribution under the homoschedasticity hypothesis, where *r* is the number of edges and *P* the number of nodes of the graph. Here, we will use a permutational approach on the samples.

Even if the IPS algorithm implemented in `qpgraph (`[@gks866-B22]) is one of most computationally efficient, in some cases (very large and complex pathways) it is highly computationally demanding (e.g. for diverse pathways the IPS algorithms takes even several days to converge) and sometimes it has problems of convergence. Therefore, with `clipper`, we have also investigated the possibility of computing the maximum-likelihood estimate of the covariance matrices using the approach of Friedman *et al.* ([@gks866-B23]), implemented in the R package `glasso`, where we have specified the indices of entries of the inverse covariance matrix to be constrained to zero and set the regularization parameter equal to zero.

As expected, the estimates of the covariance matrices obtained by `glasso` with no regularization and with the IPS algorithm are the same. However, we do not find significant improvement in the computational efficiency and both approaches show the same average computation time.

To compare portions of the pathways, with the aim of identifying subgroups of genes which appear to drive differences (deregulations) of the entire structure, `clipper` performs the above described tests on each single clique. To this end, the moral graph is first triangulated (if needed). As the cliques are complete connected subgraphs, the IPS algorithm is not required to estimate covariances.

STEP 2: IDENTIFICATION OF RELEVANT SIGNAL PATHS
===============================================

Using the structure of the junction tree as a backbone, `clipper` empirically identifies the portions of the tree mostly associated to the phenotype. For each pathway and the corresponding moralized graph, our approach is based on three main steps: (i) construction of the junction tree; (ii) identification of paths and corresponding sub-paths; and (iii) computation of the relevance of the sub-paths as specified below.

We define a *path* as the path connecting the root clique with a leaf clique \[identified by maximum cardinality search (mcs) algorithm\]. For each clique along the paths, we consider the *P*-value of the test on homoschedasticity as weight *w* of the clique. From now on, such quantities will loose their probability interpretation although they will still reflect the importance of the clique difference between the experimental conditions. A weight will be considered to be meaningful if it is \<. In our analysis we set ; however, different cut-offs can be used. On each path, we select the portions of the path composed by consecutive meaningful cliques containing at most one non-meaningful clique. Such portions define the so called *sub-paths*.

An example of the above described steps is given in [Figure 1](#gks866-F1){ref-type="fig"}. Panel A represents a junction tree with root clique *c*1 and three leaf cliques, i.e. *c*8, *c*10 and *c*12. Meaningful cliques are highlighted in red. Panel B represents the three paths derived from the junction tree. Panel C reports the four sub-paths which can be extracted from the path. Figure 1.Toy example of step 2 `clipper` approach. Panel **A**, the construction of the junction tree with significant cliques in red. Panel **B**, identification of the *paths* in the tree. Panel **C**, identification of all the *sub-paths* within each *path*. Panel **D**, selection of the best *sub-path* for each *path* and cluster analysis for sub-path collapse. Panel **E** Final *sub-path* selected.

The relevance of each sub-path is computed as follows. Let be the length of sub-path *j*, with *j* = 1, ... , *J*. Given the weight of each clique *i* in the sub-path *j*, , the relevance is calculated according to [Equation (2)](#gks866-M2){ref-type="disp-formula"}. Respecting the ordering of the cliques in the sub-path, for each clique *i* in sub-path *j*, we compute the quantity where is defined as Then, the relevance of sub-path *j* is defined to be the maximum of . To compare the relevance of sub-paths of different lengths, we introduce the standardized relevance where *m* is the position of the along the sub-path *j*. Finally, for each path, the sub-path with the maximum is selected as its relevant signal path. At the end of this procedure, a relevant signal path is identified for each path.

`clipper` results consist of a number of relevant signal paths. In most of the cases, paths and sub-paths are highly overlapping (see, e.g., sub-paths 1b, 2 and 3 in [Figure 1](#gks866-F1){ref-type="fig"}). Thus, `clipper` implements a pruning procedure using a cluster analysis approach. We define the dissimilarity measure between sub-paths *A* and *B*, *d*(*A, B*), as where A and B are the sets of genes composing sub-paths *A* and *B*, is the cardinality of sets difference and is the cardinality of the set *A* (similarly are defined and ). We perform a cluster analysis and collapse sub-paths with (taking the sub-path with the highest relevance). For our analysis, we set ; however, `clipper` allows the selection of a different threshold. For a numerical example, see panel E of [Figure 1](#gks866-F1){ref-type="fig"}.

RESULTS
=======

Rationale
---------

Different experimental conditions are usually compared in terms of their gene expression mean differences. In the univariate case, if a gene increases or decreases significantly its mean expression in one condition with respect to the other, it is said to be differentially expressed and it is assumed to be involved in the biological process under study. It is easy to generalize the previous concept to the multivariate setting; if a gene set changes significantly its multivariate mean expression in one condition with respect to the other, it is said to be differentially expressed. However, the difference in mean expression levels does not necessarily result in a change of the interaction strength among genes. In this case, we will have pathways with significant altered mean expression levels but unaltered biological interactions.

On the contrary, if transcripts abundances ratios are altered, we expect a significant alteration not only of their mean expression levels, but also of the strength of their connections, resulting in pathways with completely corrupted functionality. Therefore, to look for pathways strongly involved in a biological process, we should look at pathways with both mean and variance significantly altered.

`clipper` is based on a two-step approach: (i) it selects pathways with both covariance matrices and means significantly different between experimental conditions; and (ii) on such pathways, it identifies the sub-paths mostly associated to the phenotype. `clipper` is freely available as an R package at <http://romualdi.bio.unipd.it/> in Software section.

In this section, we provide (i) a simulation study to test the specificity of our approach; and (ii) an application of `clipper` on two real datasets along with a comparison with GSEA ([@gks866-B3]) (non-topological method), SPIA ([@gks866-B11]) and BPA ([@gks866-B6]) (topological methods). Differently from BPA, SPIA requires a list of DEGs. Here, we used empirical Bayes test ([@gks866-B1]) to identify DEGs (implemented in `limma` Bioconductor package). On real datasets, `clipper` step 2 will be applied to one of the pathways identified in step 1.

Simulation
----------

As some paths may be declared relevant by `clipper` step 2 simply as a consequence of type I errors in `clipper` step 1, we developed a simulation study. For 10 000 runs, we generated two samples, one for each condition, from the same graphical model and tested equality of concentration matrices and mean vectors for the whole pathway and all the cliques. Under this scenario, at the nominal level we expected: (i) for each test, a number of rejections around 5%; (ii) a scattered location along the junction tree of the statistically significant cliques. (ii) implies that the length of significant paths identified by `clipper` step 1 should be rarely (about 5%) longer than 1. Results shown in [Supplementary Table S1](http://nar.oxfordjournals.org/cgi/content/full/gks866/DC1) demonstrate that our procedures have an excellent control of type I error in step 1 and very appreciably respond to expectations in step 2, even with exceptionally low sample sizes.

Application: ALL dataset
------------------------

The dataset we use for this comparison was published by Chiaretti *et al.* ([@gks866-B24]) and characterizes gene expression signatures in acute lymphocytic leukemia (ALL) cells associated with known genotypic abnormalities in adult patients. Several distinct genetic mechanisms lead to ALL malignant transformations deriving from distinct lymphoid precursor cells that have been committed to either T-lineage or B-lineage differentiation. Chromosome translocations and molecular rearrangements are common events in B-lineage ALL and reflect distinct mechanisms of transformation. The relative frequencies of specific molecular rearrangements differ in children and adults with B-lineage ALL. The BCR breakpoint cluster region and the c-abl oncogene 1 (BCR/ABL) gene rearrangement occurs in about 25% of cases in adult ALL, and much less frequently in pediatric ALL.

Data are available at the Bioconductor site (<http://www.bioconductor.org/help/publications/2003/Chiaretti/chiaretti2/>). Expression values, appropriately normalized according to robust multiarray analysis (rma) and quantile normalization, derived from Affymetrix single channel technology, consist of 37 observations from one experimental condition (, BCR; presence of BCR/ABL gene rearrangement) and 41 observations from another experimental condition (, NEG; absence of rearrangement). Probes platform have been annotate using EntrezGene custom CDF version 14 ([@gks866-B25]). Step 1 resultsGiven the presence of the BCR/ABL chimera, we expect that all the pathways including BCR and/or ABL1 will be impacted. The KEGG pathways found to be significantly involved (Bonferroni adjusted *P*-value ) in the difference between translocation positive and negative patients by `clipper` step 1 analysis are reported in [Table 1](#gks866-T1){ref-type="table"}. Firstly, it is worth noting that with an adjusted *P*-value `clipper` identifies as significantly deregulated almost all (7 out of 9 *P*-value = 3.279616e--06) pathways including BCR and/or ABL genes (in red [Table 1](#gks866-T1){ref-type="table"}). On the contrary, GSEA, SPIA and BPA did not find any significantly altered pathways using Bonferroni adjusted *P*-value . However, if uncorrected *P*-value is considered, SPIA and GSEA identify 2 out of 9 (*P*-value = 0.18) pathways, including either ABL and/or BCR genes ([Table 1](#gks866-T1){ref-type="table"}), while BPA identifies only one. Table 1.KEGG significant pathways of according to the test on the means and the test on the concentration matricesIDPathway nameAdj. *P*-values test 1[^a^](#gks866-TF1){ref-type="table-fn"}Adj. *P*-values test 2[^b^](#gks866-TF2){ref-type="table-fn"}SPIA^\$^BPA^\$^GSEA^\$^1Adherens junction00.00e + 00Yes2Cell cycle00.00e + 00Yes3Dilated cardiomyopathy00.00e + 004Measles00.00e + 005Prostate cancer00.00e + 00Yes6Regulation of actin cytoskeleton00.00e + 00Yes7Vascular smooth muscle contraction00.00e + 008Wnt signaling pathway00.00e + 00YesYes9Natural killer cell-mediated cytotoxicity05.76e − 1410Bacterial invasion of epithelial cells07.68e − 1411Melanogenesis01.54e − 13Yes12Tight junction08.34e − 12Yes13Toll-like receptor signaling pathway01.68e − 10Yes14Viral myocarditis02.63e − 10Yes15Axon guidance01.31e − 0916Basal cell carcinoma05.90e − 09YesYes17Insulin signaling pathway01.39e − 08Yes18Acute myeloid leukemia02.44e − 0819Neurotrophin signaling pathway06.69e − 0820Glycolysis/gluconeogenesis08.00e − 0821Shigellosis02.04e − 0722TGF-beta signaling pathway03.71e − 0723Leukocyte transendothelial migration09.40e − 07Yes24T cell receptor signaling pathway03.37e − 0625Chronic myeloid leukemia04.40e − 0626Leishmaniasis01.65e − 0527Fructose and mannose metabolism01.78e − 0528Systemic lupus erythematosus06.32e − 0529Pyruvate metabolism01.71e − 0430Fc gamma R-mediated phagocytosis06.34e − 03Yes31RIG-I-like receptor signaling pathway07.03e − 03Yes32Pathogenic *Escherichia coli* infection08.13e − 03YesYes33B cell receptor signaling pathway02.77e − 02[^1][^2][^3][^4]

Moreover, most of the other pathways identified by `clipper` are strongly coherent with experimental findings on BCR/ABL mechanism. In fact, many signaling proteins have been shown to interact with BCR/ABL through various functional domains/motifs (e.g. GRB2, CRKL, CRK, SHC, 3BP2, ABL-interacting protein 1 and 2, and CRK-associated substrate (CAS)), and/or to become phosphorylated in BCRABL-expressing cells (e.g. CRKL, CRK, SHC, GAB2, CBL, CAS, the p85 subunit of PI3K, FES, paxillin and talin). These proteins, in turn, activate a range of signaling pathways identified by `clipper` (in blue [Table 1](#gks866-T1){ref-type="table"}) that activate proteins such as RAS, PI3K,A KT, JNK, SRC family kinases, protein and lipid phosphatases, and their respective downstream targets, as well as transcription factors such as the STATs, nuclear factor-kB and MYC. Most of these findings were observed from experiments *in vitro* systems, or from studies of the properties of cells derived from leukaemia patients with particular stages of disease ([@gks866-B26]). Step 2 resultsFocusing on CML pathway that contains exactly BCR/ABL fusion gene, `clipper` identifies a sub-path that fits perfectly with experimental findings. In particular, the highest scoring sub-path is that one starting from BCR/ABL toward the oncogene TP53 ([Figure 2](#gks866-F2){ref-type="fig"}). It is known, in fact, that the BCR/ABL fusion protein in CML cells, promotes the accumulation of p53 and that, in contrast to the activation of p53 by c-Abl, its oncogenic form, BCR/ABL, counteracts the growth inhibitory activities of p53 by modulating the p53-MDMD2 loop. Thus, it appears that by modulating the p53-MDMD2 loop, c-Abl and its oncogenic forms critically determine the type and extent of the cellular response to DNA damage ([@gks866-B27]). Figure 2.`clipper` results on chronic myeloid leukaemia (CML) KEGG pathway. Panel **A**, junction tree with significant cliques in blue. The highest scored *sub-path* is highlighted with blue border. Panel **B**, CML pathway with genes belonging to significant cliques in red or green according to their expression mean differences (translocation positive versus negative patients). Panel **C**, the original KEGG CML layout with complexes belonging to the sub-path identified colored according to their expression.

It is worth noting that the signal path obtained by `clipper` would have not been identified using just the list of DEGs belonging to this pathway. Only ABL1 and NFKBIA, in fact, are identified by empirical Bayes test ([@gks866-B1]) as differentially expressed with .

Application: LGMDs dataset
--------------------------

Limb girdle muscular dystrophies (LGMDs) are a group of muscular diseases with heterogeneous clinically and genetically features. Globally, they present progressive muscle weakness caused by progressive muscle waste combined with an increase of muscle connective tissue. We analyse a dataset containing 10 LGMD type 2A (LGMD2A) and 10 type 2B (LGMD2B) samples ([@gks866-B28]).

LGMD2A is caused by a mutation in the gene calpain3 ([@gks866-B29]) that codes for a cysteine protease that cleaves cytosckeletal and myofibrillar proteins and serves to maintain proper functions and structure of the sarcomere ([@gks866-B30]). LGMD2B is caused by a mutation in the gene dysferlin that codes for a sarcolemma protein involved in membrane repair and muscle regeneration ([@gks866-B31]). Together with desmoyokin (AHNAK), dysferlin forms the dysferlin protein complex involved in the maintenance of the sarcolemma integrity ([@gks866-B32]). AHNAK is also a substrate of calpain3, and after the cleavage AHNK is not able to bind dysferlin anymore confirming the mutual influence that calpain3 and dysferlin protein exert each other ([@gks866-B32]). Thus, we expect few molecular differences between these pathologies. Step 1 resultsIn the analysis for LGMDs, we used Reactome and KEGG databases stored in graphite. Firstly, we identify the involvement of Apoptosis (e.g. pathways 1 and 4 in [Table 2](#gks866-T2){ref-type="table"}). In case of stress signals, proapoptotic BCL-2 family proteins are activated and subsequently interact with and inactivate antiapoptotic BCL-2 proteins. This interaction leads to the destabilization of the mitochondrial membrane and release of apoptotic factors that reduce muscle cell survival in LGMD2A ([@gks866-B33]). Moreover, `clipper` results help in formulating novel hypothesis on this case study. Specifically, we found many pathways referred to MAPK signaling (e.g. pathways 2 and 5 in [Table 2](#gks866-T2){ref-type="table"}). Our results seem in agreement with ([@gks866-B34]) that recently showed the role of MAPK signaling pathway in the LMNA-associated degenerative process and the similarity of the regulatory processes between LGMD2A, LGMD2B and LMNA-associated muscular dystrophy regardless of the causative gene. Step 2 resultsWith the step 2 of `clipper` analysis, we are able to reach an even deeper level of accurateness. We focused on Intrinsic pathway of apoptosis. [Figure 3](#gks866-F3){ref-type="fig"} shows that the signal sub-path identified by `clipper` include BAX, BID, BCL2 and BAD that play a central role in leading to apoptosis. Figure 3.Intrinsic pathway of apoptosis. Panel **A**, junction tree with significant clique in blue. The highest scored *sub-path* is highlighted with blue border. Panel **B**, native pathway with genes belonging to significant cliques in red or green according to their expression mean differences (LGMD2A versus LGMD2B). Table 2.List of significant KEGG and Reactome pathways according to the test on the means and the test on the concentration matricesPathway nameAdj. *P*-values test 1[^a^](#gks866-TF3){ref-type="table-fn"}Adj *P*-values test 2[^b^](#gks866-TF4){ref-type="table-fn"}1KEGG: RIG-I-like receptor signaling pathway05.68e − 132Reactome: GRB2:SOS provides linkage to MAPK signaling for integrins03.22e − 133Reactome: DCC-mediated attractive signaling08.50e − 094Reactome: Intrinsic pathway for apoptosis01.07e − 065Reactome: p130Cas linkage to MAPK signaling for integrins01.37e − 066Reactome: TRAIL signaling01.50e − 027Reactome: signal regulatory protein (SIRP) family interactions02.00e − 028Reactome: activation of BH3-only proteins12.16e − 03[^5][^6][^7]

CONCLUSIONS
===========

Here, we present `clipper`, a novel two-step empirical method for pathway analysis able to dissect the complexity of a pathway identifying the portions mostly associated to the biological process studied.

Our empirical approach is fundamentally different from previous ones for two reasons. We take into account not only expression changes but also differences in transcript concentrations, allowing the identification of pathways with their functionality completely corrupted. We are able to go to the finest details of the pathway structure, identifying the signal transduction path that is the principal cause of the pathway deregulation.

`clipper` efficacy has been validated on two expression datasets of completely different biological problems (cancer and muscle disorders). In both cases, we obtained interesting results strongly coherent with experimental findings available in literature. Moreover, our results demonstrate the utility of `clipper` not only in the result comprehension but also in driving the experimenter in formulating new hypothesis. We therefore believe that `clipper` would become an important tool for gene expression data interpretation.

SUPPLEMENTARY DATA
==================

[Supplementary Data](http://nar.oxfordjournals.org/cgi/content/full/gks866/DC1) are available at NAR Online: Supplementary Table 1 and Supplementary Figures 1 and 2.
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Gaussian graphical models
=========================

We report here a concise review of Gaussian Graphical Models theory. A graph *G* is a pair , where *V* is a finite set of vertices and the set of edges is the set of ordered pairs of distinct vertices. If both and , the edge (*u, v*) is said to be undirected. If but , the edge (*v, u*) is said to be directed.

A DAG is a directed graph without cycles. Given a DAG, a moral graph is the undirected graph obtained from the DAG by adding undirected edges between all pairs of vertices that have a child in common (if they are not already present) and then by rendering all edges undirected.

If *G* is undirected, then a subgraph is *complete* if all its vertices are joined by an edge. Any *complete* subgraph is a *clique*. A maximal complete subgraph (with respect to ) is a maximal *clique*. In a graphical models context only maximal cliques are relevant in estimation problems and therefore we will always use the term clique with the meaning of maximal clique.

A triple (*A, B, C*) of disjoint subsets of *V* of an undirected graph *G* is a decomposition of *G* if , *C* is a complete subset of *V* and *C* separates *A* and *B*. An undirected graph is *decomposable* if either it is complete or it possesses a proper decomposition (*A, B, C*) such that both subgraphs and are decomposable.

A *triangulated graph* (or *chordal graph*) is an undirected graph with the property that every cycle of length has two non-consecutive vertices that are adjacent. An important result is that an undirected graph is decomposable if and only if it is triangulated ([@gks866-B19], p. 9). If a graph is not triangulated, it is possible to add extra edges so that the resulting graph is triangulated. It is well known that the problem of obtaining an optimal triangulation (i.e. finding the smallest number of edges to be added) is NP-hard and therefore we rely on the heuristic algorithm developed in the R package `gRbase`, implemented in the function `triangulate`.

A *junction tree of cliques* for a graph *G* is a tree having the cliques of *G* as nodes and satisfying the *running intersection property* according to which, for any cliques and in the tree, every clique on the path connecting and contains . Decomposability is a necessary and sufficient condition for the existence of a junction tree. We build a junction tree by finding a running intersection property ordering of the cliques via the maximum cardinality search algorithm (mcs, implemented in the `rip` function of the `gRbase` R package).

A Gaussian graphical model with dependence graph *G* = (*V, E*) where can be defined as the multivariate normal distribution where is the set of symmetric positive definite matrices with null elements corresponding to the missing edges of *G*.

[^1]: In red those pathways including BCR and/or ABL genes, in blue those pathways coherent with experimental evidences.

[^2]: ^a^Test on the mean with Bonferroni correction.

[^3]: ^b^Test on the concentration matrices with Bonferroni correction.

[^4]: ^\$^SPIA, BPA and GSEA results using raw *P*-value .

[^5]: BPA cannot be performed on Reactome database and GSEA does not identify significantly deregulated pathways, neither with Bonferroni adjusted *P*-values nor with nominal *P*-values.

[^6]: ^a^Test on the mean with Bonferroni correction.

[^7]: ^b^Test on the concentration matrices with Bonferroni correction.
